Tag

trial- Pagina 3

1 minuto di lettura

Bioheart (02185.HK) announces clinical result for Iberis-HTN at CIT 2023

(Adnkronos) – SHANGHAI, June 30, 2023 /PRNewswire/ — Bioheart (02185.HK), together with its holding subsidiary Angiocare announces the clinical result for Iberis-HTN at China Interventional Therapeutics 2023. Iberis-HTN is a prospective, multicenter, blinded,

Immediapress

Pharming announces first patient enrolled in pediatric clinical trial of leniolisib

(Adnkronos) – The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency LEIDEN, Netherlands, Feb. 21, 2023 /PRNewswire/ — Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam:

Adagio Medical Announces Completion of Enrollment in Cryocure-VT Trial, Maps the Pathway to CE-Mark of vCLAS™ VT Ablation Catheter

Immediapress

(Adnkronos) – LAGUNA HILLS, Calif., May 3, 2023 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF)

First Clinical Study of its Kind Shows Positive Impacts from Astaxanthin During Sport Recovery

Immediapress

(Adnkronos) – BRANCHBURG, N.J., March 28, 2023 /PRNewswire/ — A new clinical trial study, published in Frontiers in Nutrition, showed that four weeks of

Antinori (Spallanzani): “I dati Covid dal mondo reale hanno fatto riadattare le terapie”

venerdì, 5 Maggio 2023

Salute

(Adnkronos) – “Gli studi real world evidence sul Covid sono stati fondamentali perché l’evolutività impressionate del Covid e il cambiamento delle varianti hanno reso i trial registrativi quasi vecchi, a un certo

Alphyn Biologics Reports Positive Pediatric Results from Phase 2a Atopic Dermatitis Trial

giovedì, 4 Maggio 2023

Immediapress

(Adnkronos) – Trial meets all primary and secondary endpoints across pediatric population ages 2 and older ANNAPOLIS, Md. and MALAGA, Spain, May 4, 20232 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company

Alphyn Biologics Presents Pediatric Data from Atopic Dermatitis Trial at European Society for Pediatric Dermatology Congress

giovedì, 27 Aprile 2023

Immediapress

(Adnkronos) – ANNAPOLIS, Md., April 27, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, will present for the first time new pediatric data from its Phase 2a

Indietro 1 2 3

trial- Pagina 3

Bioheart (02185.HK) announces clinical result for Iberis-HTN at CIT 2023

Pharming announces first patient enrolled in pediatric clinical trial of leniolisib

Adagio Medical Announces Completion of Enrollment in Cryocure-VT Trial, Maps the Pathway to CE-Mark of vCLAS™ VT Ablation Catheter

First Clinical Study of its Kind Shows Positive Impacts from Astaxanthin During Sport Recovery

Antinori (Spallanzani): “I dati Covid dal mondo reale hanno fatto riadattare le terapie”

Alphyn Biologics Reports Positive Pediatric Results from Phase 2a Atopic Dermatitis Trial

Alphyn Biologics Presents Pediatric Data from Atopic Dermatitis Trial at European Society for Pediatric Dermatology Congress

Primo piano

Italia-Spagna, la sospensione di Schengen non sarà rinnovata

Blocco Tir, governo “sblocca” in Sicilia e Calabria, ma il Golfo di Napoli a rischio isolamento

Dopo gli scontri: cosa prevede il decreto e quali poteri hanno i militari

Il gioco sporco de “la Repubblica” che evoca il Cile di Pinochet in Italia

Schlein: “Serve prevenzione non repressione su sicurezza. Colle ha stoppato poteri ai militari” | Video

Sponsor

Suggerimenti

trial- Pagina 3

Primo piano

Sponsor